Perthera CEO Gary Gregory talks with DocWire News to explain how Perthera’s Precision Oncology Platform is transforming precision medicine in healthcare today, with proven results and advanced technology.
Mr. Gregory is an experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the MedTech Sector. His experience spans numerous companies and positions, including Executive Officer roles across several successful start-up companies, and leadership roles in Fortune 250 companies.
McLean, VA // Perthera, University of Virginia Health System (UVA) and Eastern Virginia Medical School (EVMS) Awarded $500,000 by Virginia Catalyst Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
Molecular tumor profiling, which enables physicians to match patients to targeted therapies, is on the rise. Read the latest report published in the British Journal of Cancer.
Dr. Mike Pishvaian discusses results from Perthera and PanCAN’s Know Your Tumor study, presented as Abstract 191 at ASCO GI 2019 in San Francisco, CA.
Using real-world data from over 640 patients with pancreatic cancer, this landmark study demonstrated a 2.2 fold increase in progression-free survival for those being treated with a molecularly-matched therapy. Attached is a pdf of the press release.
McLean, VA –(PR.com)– Perthera Inc.’s, Subha Madhavan, PhD, Chief Bioinformatics Officer, will be speaking at the 11th Annual Fall Conference of Health 2.0 on Healthcare Innovations, Oct 1 – 4 in Santa Clara, CA, in the Personalized Health Track “Turning Data into Value.”